Beam Therapeutics Inc. (BEAM) shareholders
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)
Close on Nov 13, 2026Market cap $2.36BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
109M of 103M shares
Institutional holders
277
59 new, 31 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 31 sales
Net sold $19.74M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (13.60%) | 13,766,518 | 13.60% | 13G (passive) amendment | Sep 30, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (12.60%) | 12,750,369 | 12.60% | 13G (passive) amendment | Dec 31, 2025 |
| Catherine D. Wood Joint filing with ARK Investment Management LLC (12.29%) | 12,467,189 | 12.29% | 13G (passive) amendment | Dec 31, 2025 |
| Spokes, Andrew J. M. Joint filing with Farallon Capital Management, L.L.C. (9.99%), Dapice Joshua J. (9.99%) and 13 more | 10,282,210 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| ARK Investment Management LLC Joint filing with Catherine D. Wood (9.95%) | 10,234,862 | 9.95% | 13G (passive) amendment | Jun 30, 2026 |
| Short Daniel S. Joint filing with Wehrly, Mark C. (9.99%), Saito Edric C. (9.99%) and 15 more | 10,141,856 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Roberts, Jr., Thomas G. Joint filing with Wehrly, Mark C. (9.90%), Short Daniel S. (9.90%) and 17 more | 8,239,123 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 7,499,930 | 7.50% | 13G (passive) amendment | Mar 31, 2025 |
| State Street Corporation | 5,228,529 | 5.20% | 13G (passive) | Dec 31, 2025 |
| Vanguard Capital Management | 5,122,475 | 5.02% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BEAM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 12,609,002 | 12.21% | $432.74M | +156,803 | 0.02% |
| Farallon Capital Management LLC | 10,236,396 | 9.91% | $351.31M | +101,700 | 1.62% |
| ARK Investment Management LLC | 10,234,862 | 9.91% | $351.26M | −1,898,571 | 2.28% |
| BlackRock, Inc. | 8,997,542 | 8.71% | $308.80M | +509,973 | 0.00% |
| State Street Corp | 5,827,122 | 5.64% | $199.99M | +127,857 | 0.01% |
| Vanguard Portfolio Management LLC | 4,921,259 | 4.76% | $168.90M | +350,462 | 0.01% |
| Vanguard Capital Management LLC | 4,599,437 | 4.45% | $157.85M | +222,063 | 0.00% |
| ARCH Venture Management, LLC | 4,540,132 | 4.40% | $155.77M | – | 14.16% |
| Sumitomo Mitsui Trust Holdings, Inc. | 3,455,043 | 3.35% | $118.58M | −370,542 | 0.07% |
| Nikko Asset Management Americas, Inc. | 3,455,043 | 3.35% | $118.54M | −370,542 | 1.53% |
| Price T Rowe Associates Inc /Md/ | 3,415,239 | 3.31% | $117.21M | +702,009 | 0.01% |
| Kynam Capital Management, LP | 2,840,792 | 2.75% | $97.50M | −841,393 | 5.39% |
| Geode Capital Management, LLC | 2,596,963 | 2.51% | $89.14M | +178,371 | 0.00% |
| Dimensional Fund Advisors LP | 2,225,844 | 2.15% | $76.40M | +71,269 | 0.01% |
| Morgan Stanley | 1,950,969 | 1.89% | $66.96M | +1,302,705 | 0.00% |
| Contrarius Group Holdings Ltd | 1,614,538 | 1.56% | $55.41M | +1,081,095 | 2.55% |
| UBS Asset Management Americas Inc | 1,551,781 | 1.50% | $53.26M | −101,933 | 0.01% |
| Two Sigma Investments, LP | 1,388,227 | 1.34% | $47.64M | +177,374 | 0.03% |
| Casdin Capital, LLC | 1,350,000 | 1.31% | $46.33M | – | 2.32% |
| Goldman Sachs Group Inc | 1,310,059 | 1.27% | $44.96M | +304,316 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 277 | 109M | 100.0% | 59 / 93 | 76 / 31 | 10M | 9M |
| Q1 2026 | 253 | 108M | 100.0% | 55 / 89 | 62 / 42 | 19M | 7M |
| Q4 2025 | 247 | 107M | 100.0% | 64 / 77 | 63 / 31 | 12M | 10M |
| Q3 2025 | 219 | 107M | 100.0% | 40 / 79 | 53 / 35 | 9M | 11M |
| Q2 2025 | 217 | 109M | 100.0% | 36 / 84 | 65 / 55 | 17M | 10M |
| Q1 2025 | 238 | 101M | 98.2% | 43 / 101 | 47 / 32 | 23M | 3M |
| Q4 2024 | 231 | 81M | 78.9% | 36 / 82 | 65 / 23 | 8M | 6M |
| Q3 2024 | 221 | 80M | 77.1% | 28 / 73 | 68 / 19 | 16M | 7M |
| Q2 2024 | 214 | 78M | 75.8% | 36 / 73 | 62 / 41 | 17M | 18M |
| Q1 2024 | 221 | 79M | 76.5% | 55 / 81 | 46 / 18 | 12M | 7M |
| Q4 2023 | 185 | 74M | 71.3% | 32 / 65 | 55 / 38 | 14M | 8M |
| Q3 2023 | 194 | 67M | 65.3% | 33 / 79 | 39 / 30 | 7M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
245 funds held BEAM in Q2 2026, 64% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BEAM | Value | % of fund | As of |
|---|---|---|---|---|---|
| ARK Innovation ETF | 6,079,070 | 5.89% | $155.14M | 2.79% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 3,461,620 | 3.35% | $113.99M | 0.12% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,376,280 | 3.27% | $115.87M | 1.08% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,273,307 | 3.17% | $112.34M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,545,006 | 2.46% | $87.34M | 0.11% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,361,140 | 2.29% | $81.03M | 0.04% | Jun 30, 2026 |
| ARK Genomic Revolution ETF | 2,304,800 | 2.23% | $58.82M | 3.78% | Jul 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,359,986 | 1.32% | $46.67M | 0.10% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,141,851 | 1.11% | $39.19M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,084,817 | 1.05% | $27.68M | 0.08% | Jul 31, 2026 |
| Fidelity Growth Company K6 Fund | 980,134 | 0.95% | $32.28M | 0.12% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 842,092 | 0.82% | $28.90M | 0.24% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 820,377 | 0.79% | $28.16M | 0.18% | Jun 30, 2026 |
| Fidelity Series Growth Company Fund | 820,099 | 0.79% | $27.01M | 0.11% | May 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 818,640 | 0.79% | $28.10M | 0.29% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John M. Evans | CEO, Director | 1,150,205 | 1.11% | Oct 16, 2026 |
| Bethany J. Cavanagh | SVP, Finance and Treasurer | 50,984 | 0.05% | Oct 2, 2026 |
| Giuseppe Ciaramella | President | 253,911 | 0.25% | Sep 25, 2026 |
| Amy Simon | Chief Medical Officer | 85,696 | 0.08% | Jul 29, 2026 |
| Christine Bellon | Chief Legal Officer | 109,711 | 0.11% | Apr 6, 2026 |
| Sravan Kumar Emany | Chief Financial Officer | 105,456 | 0.10% | Apr 2, 2026 |
| Graham K. Cooper | Director | 600 | 0.00% | Jun 5, 2026 |
| Christi Shaw | Director | – | – | Jun 5, 2026 |
| Mark Fishman | Director | 17,007 | 0.02% | Jun 5, 2026 |
| Kathleen E. Walsh | Director | – | – | Jun 5, 2026 |
| John Maraganore | Director | – | – | Jun 5, 2026 |
| Chirfi Guindo | Director | – | – | Jun 5, 2026 |
| Carole Ho | Director | – | – | Jun 6, 2025 |
| Llc Fmr | 10% owner | 1,695,828 | 1.64% | Jun 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John M. Evans CEO, Director | Oct 16, 2026 | Sale(10b5-1 plan) | −25,000 | $23.98 | $599.60K | 1,047,205 |
| John M. Evans CEO, Director | Oct 16, 2026 | Option exercise | +25,000 | $1.03 | $25.75K | 1,072,205 |
| John M. Evans CEO, Director | Oct 15, 2026 | Sale(10b5-1 plan) | −25,000 | $23.57 | $589.15K | 1,047,205 |
| John M. Evans CEO, Director | Oct 15, 2026 | Option exercise | +25,000 | $1.03 | $25.75K | 1,072,205 |
| Bethany J. Cavanagh SVP, Finance and Treasurer | Oct 1, 2026 | Sale(10b5-1 plan) | −187 | $24.41 | $4.56K | 50,984 |
| Giuseppe Ciaramella President | Sep 24, 2026 | Gift | −123,407 | – | – | 130,504 |
| Amy Simon Chief Medical Officer | Jul 27, 2026 | Sale(10b5-1 plan) | −16,667 | $25.74 | $429.01K | 85,696 |
| Amy Simon Chief Medical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −373 | $34.73 | $12.95K | 102,363 |
| John M. Evans CEO, Director | Jun 30, 2026 | Sale(10b5-1 plan) | −1,900 | $34.84 | $66.20K | 1,047,205 |
| John M. Evans CEO, Director | Jun 30, 2026 | Sale(10b5-1 plan) | −23,100 | $34.26 | $791.41K | 1,049,105 |
| John M. Evans CEO, Director | Jun 30, 2026 | Option exercise | +25,000 | $1.03 | $25.75K | 1,072,205 |
| John M. Evans CEO, Director | Jun 29, 2026 | Option exercise | +18,663 | $0.67 | $12.50K | 1,065,868 |
| John M. Evans CEO, Director | Jun 29, 2026 | Option exercise | +6,337 | $1.03 | $6.53K | 1,072,205 |
| John M. Evans CEO, Director | Jun 29, 2026 | Sale(10b5-1 plan) | −13,421 | $35.13 | $471.48K | 1,058,784 |
| John M. Evans CEO, Director | Jun 29, 2026 | Sale(10b5-1 plan) | −11,579 | $35.91 | $415.80K | 1,047,205 |
| Llc Fmr 10% owner | Jun 26, 2026 | Sale | −251,488 | $35.26 | $8.87M | 854,583 |
| Llc Fmr 10% owner | Jun 25, 2026 | Sale | −33,372 | $35.12 | $1.17M | 1,106,071 |
| Giuseppe Ciaramella President | Jun 17, 2026 | Option exercise | +29,000 | $1.03 | $29.87K | 253,911 |
| Giuseppe Ciaramella President | Jun 17, 2026 | Option exercise | +6,505 | $0.67 | $4.36K | 224,911 |
| John M. Evans CEO, Director | Apr 1, 2026 | Sale(10b5-1 plan) | −30,078 | $24.58 | $739.32K | 1,047,205 |
| Bethany J. Cavanagh SVP, Finance and Treasurer | Apr 1, 2026 | Sale(10b5-1 plan) | −3,242 | $24.58 | $79.69K | 51,171 |
| Christine Bellon Chief Legal Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −5,956 | $24.58 | $146.40K | 109,711 |
| Giuseppe Ciaramella President | Apr 1, 2026 | Sale(10b5-1 plan) | −11,810 | $24.58 | $290.29K | 218,406 |
| Amy Simon Chief Medical Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −6,700 | $24.58 | $164.69K | 102,735 |
| Giuseppe Ciaramella President | Mar 31, 2026 | Award | +40,000 | – | – | 230,216 |
| Sravan Kumar Emany Chief Financial Officer | Mar 31, 2026 | Award | +31,750 | – | – | 105,456 |
| Christine Bellon Chief Legal Officer | Mar 31, 2026 | Award | +20,000 | – | – | 115,667 |
| Amy Simon Chief Medical Officer | Mar 31, 2026 | Award | +31,750 | – | – | 109,114 |
| Bethany J. Cavanagh SVP, Finance and Treasurer | Mar 31, 2026 | Award | +20,000 | – | – | 54,813 |
| John M. Evans CEO, Director | Mar 31, 2026 | Award | +90,000 | – | – | 1,076,667 |
| John M. Evans CEO, Director | Mar 31, 2026 | Sale(10b5-1 plan) | −25,000 | $22.76 | $569.00K | 986,667 |
| John M. Evans CEO, Director | Mar 31, 2026 | Option exercise | +25,000 | $0.67 | $16.75K | 1,011,667 |
| John M. Evans CEO, Director | Mar 30, 2026 | Option exercise | +25,000 | $0.67 | $16.75K | 1,011,667 |
| John M. Evans CEO, Director | Mar 30, 2026 | Sale(10b5-1 plan) | −25,000 | $22.37 | $559.25K | 986,667 |
| Giuseppe Ciaramella President | Feb 24, 2026 | Sale(10b5-1 plan) | −35,000 | $32.00 | $1.12M | 190,216 |
| Giuseppe Ciaramella President | Feb 24, 2026 | Option exercise | +35,000 | $17.00 | $595.00K | 225,216 |
| John M. Evans CEO, Director | Jan 30, 2026 | Option exercise | +25,000 | $0.67 | $16.75K | 1,011,667 |
| John M. Evans CEO, Director | Jan 30, 2026 | Sale(10b5-1 plan) | −22,094 | $28.27 | $624.60K | 989,573 |
| John M. Evans CEO, Director | Jan 30, 2026 | Sale(10b5-1 plan) | −2,906 | $29.00 | $84.27K | 986,667 |
| John M. Evans CEO, Director | Jan 29, 2026 | Sale(10b5-1 plan) | −8,667 | $29.74 | $257.76K | 986,667 |
| John M. Evans CEO, Director | Jan 29, 2026 | Sale(10b5-1 plan) | −16,333 | $29.19 | $476.76K | 995,334 |
| John M. Evans CEO, Director | Jan 29, 2026 | Option exercise | +5,664 | $0.67 | $3.79K | 1,011,667 |
| John M. Evans CEO, Director | Jan 29, 2026 | Option exercise | +19,336 | $0.67 | $12.96K | 1,006,003 |
| Christine Bellon Chief Legal Officer | Jan 22, 2026 | Sale(10b5-1 plan) | −1,371 | $34.00 | $46.61K | 95,667 |
| Bethany J. Cavanagh SVP, Finance and Treasurer | Jan 22, 2026 | Sale(10b5-1 plan) | −6,198 | $35.00 | $216.93K | 34,813 |
| Bethany J. Cavanagh SVP, Finance and Treasurer | Jan 20, 2026 | Sale(10b5-1 plan) | −3,034 | $30.12 | $91.38K | 41,011 |
| Christine Bellon Chief Legal Officer | Jan 15, 2026 | Sale(10b5-1 plan) | −559 | $35.40 | $19.79K | 97,038 |
| Christine Bellon Chief Legal Officer | Jan 15, 2026 | Sale(10b5-1 plan) | −2,111 | $33.62 | $70.97K | 113,556 |
| Christine Bellon Chief Legal Officer | Jan 15, 2026 | Sale(10b5-1 plan) | −15,959 | $34.72 | $554.10K | 97,597 |
| Christine Bellon Chief Legal Officer | Dec 31, 2025 | Sale(10b5-1 plan) | −1,254 | $27.10 | $33.98K | 115,667 |
| Amy Simon Chief Medical Officer | Dec 31, 2025 | Award | +12,500 | – | – | 77,364 |
| Sravan Kumar Emany Chief Financial Officer | Dec 31, 2025 | Sale(10b5-1 plan) | −6,294 | $27.10 | $170.57K | 73,706 |
| Llc Fmr 10% owner | Oct 27, 2025 | Sale | −459 | $26.68 | $12.25K | 14 |
| Llc Fmr 10% owner | Oct 6, 2025 | Gift | −1,232,434 | – | – | 841,231 |
| John M. Evans CEO, Director | Oct 2, 2025 | Option exercise | +25,000 | $0.67 | $16.75K | 1,011,667 |
| John M. Evans CEO, Director | Oct 2, 2025 | Sale(10b5-1 plan) | −25,000 | $24.63 | $615.75K | 986,667 |
| John M. Evans CEO, Director | Oct 1, 2025 | Option exercise | +25,000 | $0.67 | $16.75K | 1,011,667 |
| John M. Evans CEO, Director | Oct 1, 2025 | Sale(10b5-1 plan) | −25,000 | $24.51 | $612.75K | 986,667 |
| Bethany J. Cavanagh SVP, Finance and Treasurer | Oct 1, 2025 | Sale(10b5-1 plan) | −467 | $24.53 | $11.46K | 44,045 |
| Christine Bellon Chief Legal Officer | Oct 1, 2025 | Sale(10b5-1 plan) | −373 | $24.53 | $9.15K | 116,921 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
26.13%
26M shares short
Days to cover
13.7
At 2M shares a day
Change since last report
-0.6%
From 26M shares
Short volume, 20 days
61.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Beam Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 51,006 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| John M. Evans Officer, Director | Oct 16, 2026 | 25,000 | $599.60K | Oct 16, 2026 | Stock Option Exercise |
| John M. Evans Officer, Director | Oct 15, 2026 | 25,000 | $589.15K | Oct 15, 2026 | Stock Option Exercise |
| Amy Simon Officer | Jul 27, 2026 | 16,677 | $429.29K | Jul 27, 2026 | Restricted Stock |
| John M. Evans Officer, Director | Jun 30, 2026 | 25,000 | $857.69K | Jun 30, 2026 | Stock Option Exercise |
| John M. Evans Officer, Director | Jun 29, 2026 | 25,000 | $887.35K | Jun 29, 2026 | Stock Option Exercise |
| Carole Ho Director | Apr 14, 2026 | 87,784 | $2.70M | Apr 14, 2026 | Stock Option Exercise |
| John M. Evans Officer, Director | Mar 31, 2026 | 25,000 | $569.09K | Mar 31, 2026 | Stock Option Exercise |
| Amy Simon Officer | Mar 31, 2026 | 20,000 | $438.00K | Apr 2, 2026 | Restricted Stock Vesting |
| John M. Evans Officer, Director | Mar 31, 2026 | 66,874 | $1.46M | Apr 2, 2026 | Restricted Stock Vesting |
| Giuseppe Ciaramella Officer | Mar 31, 2026 | 26,250 | $574.88K | Apr 2, 2026 | Restricted Stock Vesting |
| Christine Bellon Officer | Mar 31, 2026 | 20,000 | $438.00K | Apr 2, 2026 | Restricted Stock Vesting |
| John M. Evans Officer, Director | Mar 30, 2026 | 25,000 | $559.23K | Mar 30, 2026 | Stock Option Exercise |
| Giuseppe Ciaramella Officer | Feb 24, 2026 | 35,000 | $1.12M | Feb 24, 2026 | Stock Option Exercise |
| John M. Evans Officer, Director | Jan 30, 2026 | 25,000 | $708.95K | Jan 30, 2026 | Stock Option Exercise |
| John M. Evans Officer, Director | Jan 29, 2026 | 25,000 | $734.58K | Jan 29, 2026 | Stock Option Exercise |
See a number that looks wrong?